June 16, 2024

Groundbreaking Research Identifies Likely Cause of Alzheimer’s Disease – Potential for New Treatment

A most likely cause of Alzheimers disease offers a significant finding that uses possible new avoidance and treatment chances for Australias second-leading cause of death.
Ground-breaking brand-new Curtin University-led research study has found a most likely reason for Alzheimers disease, in a significant finding that offers potential new avoidance and treatment chances for Australias second-leading cause of death.

The research study, released in the prestigious PLOS Biology journal and checked on mouse models, identified that a possible reason for Alzheimers illness was the leak from blood into the brain of fat-carrying particles transporting hazardous proteins..
Lead private investigator Curtin Health Innovation Research Institute (CHIRI) Director Professor John Mamo said his collaborative group of Australian researchers had determined the probable blood-to-brain path that can lead to Alzheimers disease, the most prevalent form of dementia worldwide.
” While we formerly understood that the trademark function of individuals dealing with Alzheimers disease was the progressive accumulation of harmful protein deposits within the brain called beta-amyloid, scientists did not understand where the amyloid stemmed from, or why it transferred in the brain,” Professor Mamo said.
” Our research shows that these harmful protein deposits that form in the brains of people coping with Alzheimers illness most likely leakage into the brain from fat bring particles in blood, called lipoproteins.
” This blood-to-brain path is significant since if we can handle the levels in blood of lipoprotein-amyloid and prevent their leak into the brain, this opens prospective new treatments to avoid Alzheimers illness and slow memory loss.”.
Building on previous award-winning research that showed beta-amyloid is made outside the brain with lipoproteins, Professor Mamos group checked the ground-breaking blood-to-brain path by genetically engineering mouse models to produce human amyloid-only liver that make lipoproteins.
” As we forecasted, the research study found that mouse designs producing lipoprotein-amyloid in the liver suffered swelling in the brain, accelerated brain cell death, and memory loss,” Professor Mamo said.
” While additional studies are now needed, this finding shows the abundance of these harmful protein deposits in the blood could possibly be attended to through a persons diet and some drugs that could specifically target lipoprotein amyloid, therefore decreasing their danger or slowing the progression of Alzheimers disease.”.
Alzheimers WA Chairman Adjunct Professor Warren Harding said the findings might have a considerable international effect for the countless individuals living with Alzheimers disease.
” Having universities like Curtin working with the pharmaceutical market is necessary if we are to tackle this destructive disease,” Mr. Harding stated.
” In Australia, around 250 people are identified with dementia daily, contributing to the incredible half a million Australians who are already coping with dementia. Without significant medical advances like the development Professor Mamos group has actually made, it is approximated that the variety of Australians living with dementia will exceed one million by 2058. This has a significant influence on carers, neighborhoods and households.”.
Professor Mamo and his research teams previous research in this area was awarded the NHMRC-Marshall and Warren Award for the most potentially transformative and ingenious research study.
Presently, the group is performing a medical trial, the Probucol in Alzheimers- medical trial, which is based upon previous findings that a historic cardiovascular agent decreases lipoprotein-amyloid production and supports cognitive efficiency in mice.
For more on this research, see Protein Made in the Liver May Cause Alzheimers Disease in the Brain.
Reference: “Synthesis of human amyloid restricted to liver lead to an Alzheimer disease– like neurodegenerative phenotype” by Virginie Lam, Ryusuke Takechi, Mark J. Hackett, Roslyn Francis, Michael Bynevelt, Liesl M. Celliers, Michael Nesbit, Somayra Mamsa, Frank Arfuso, Sukanya Das, Frank Koentgen, Maree Hagan, Lincoln Codd, Kirsty Richardson, Brenton OMara, Rainer K. Scharli, Laurence Morandeau, Jonathan Gauntlett, Christopher Leatherday, Jan Boucek, John C. L. Mamo, 14 September 2021, PLOS Biology.DOI: 10.1371/ journal.pbio.3001358.

” In Australia, around 250 people are detected with dementia daily, including to the staggering half a million Australians who are currently living with dementia. Without considerable medical advances like the breakthrough Professor Mamos group has made, it is estimated that the number of Australians living with dementia will surpass one million by 2058. This has a substantial effect on carers, families and neighborhoods.”.